Skip to main content

Advertisement

Combination strategies

Section edited by Paolo A. Ascierto

This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.

Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may en to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

Featured articles

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
Takashi Shingu, et al


Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Jenny E Hernandez-Davies, et al


What’s new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola and Michael B Atkins

Page 2 of 3

  1. Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especia...

    Authors: Giuseppe Roscilli, Claudia De Vitis, Fabiana Fosca Ferrara, Alessia Noto, Emanuela Cherubini, Alberto Ricci, Salvatore Mariotta, Enrico Giarnieri, Maria Rosaria Giovagnoli, Maria Rosaria Torrisi, Francesca Bergantino, Susan Costantini, Francesca Fenizia, Matilde Lambiase, Luigi Aurisicchio, Nicola Normanno…

    Citation: Journal of Translational Medicine 2016 14:61

    Content type: Research

    Published on:

  2. Previous studies suggest that certain transition metal complexes, such as cisplatin, are efficacious for treating various cancer types, including ovarian, lung, and breast.

    Authors: Joji Iida, Elisabeth T. Bell-Loncella, Marc L. Purazo, Yifeng Lu, Jesse Dorchak, Rebecca Clancy, Julianna Slavik, Mary Lou Cutler and Craig D. Shriver

    Citation: Journal of Translational Medicine 2016 14:48

    Content type: Research

    Published on:

  3. The majority of glioblastomas have aberrant receptor tyrosine kinase (RTK)/RAS/phosphoinositide 3 kinase (PI3K) signaling pathways and malignant glioma cells are thought to be addicted to these signaling pathw...

    Authors: Takashi Shingu, Lindsay Holmes, Verlene Henry, Qianghu Wang, Khatri Latha, Anupama E. Gururaj, Laura A. Gibson, Tiffany Doucette, Frederick F. Lang, Ganesh Rao, Liang Yuan, Erik P. Sulman, Nicholas P. Farrell, Waldemar Priebe, Kenneth R. Hess, Yaoqi A. Wang…

    Citation: Journal of Translational Medicine 2016 14:46

    Content type: Research

    Published on:

  4. Constitutive MET signaling promotes invasiveness in most primary and recurrent GBM. However, deployment of available MET-targeting agents is confounded by lack of effective biomarkers for selecting suitable pa...

    Authors: Jennifer Johnson, Maria Libera Ascierto, Sandeep Mittal, David Newsome, Liang Kang, Michael Briggs, Kirk Tanner, Francesco M. Marincola, Michael E. Berens, George F. Vande Woude and Qian Xie

    Citation: Journal of Translational Medicine 2015 13:306

    Content type: Research

    Published on:

  5. Melanoma was again a focus of attention at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, in particular the use of combination treatment strategies involving immunotherapies and/or tar...

    Authors: Paolo A Ascierto, Francesco M Marincola and Michael B Atkins

    Citation: Journal of Translational Medicine 2015 13:213

    Content type: Editorial

    Published on:

  6. V600 BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the co...

    Authors: Jenny E Hernandez-Davies, Thai Q Tran, Michael A Reid, Kimberly R Rosales, Xazmin H Lowman, Min Pan, Gatien Moriceau, Ying Yang, Jun Wu, Roger S Lo and Mei Kong

    Citation: Journal of Translational Medicine 2015 13:210

    Content type: Research

    Published on:

  7. Growing awareness of the complexity of carcinogenesis has made multimodal therapies for cancer increasingly compelling and relevant. In recent years, immunotherapy has gained acceptance as an active therapeuti...

    Authors: Anna R Kwilas, Andressa Ardiani, Renee N Donahue, Dana T Aftab and James W Hodge

    Citation: Journal of Translational Medicine 2014 12:294

    Content type: Research

    Published on:

  8. This study was conducted to determine if anti-tumor vaccination administered prior to partial debulking surgery could improve survival using a murine solid tumour model.

    Authors: Scott A Fisher, Amanda Cleaver, Devina D Lakhiani, Andrea Khong, Theresa Connor, Ben Wylie, W Joost Lesterhuis, Bruce WS Robinson and Richard A Lake

    Citation: Journal of Translational Medicine 2014 12:245

    Content type: Research

    Published on:

  9. Advances in melanoma treatment through targeted inhibition of oncogenic BRAF are limited owing to the development of acquired resistance. The involvement of BRAFV600E in metabolic reprogramming of melanoma cells ...

    Authors: Cecilie Abildgaard, Christina Dahl, Astrid L Basse, Tao Ma and Per Guldberg

    Citation: Journal of Translational Medicine 2014 12:247

    Content type: Research

    Published on:

  10. The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs. A very efficient mechanism of tumor resistance to drugs is the proton pumps-mediated acidification...

    Authors: Enrico P Spugnini, Sabrina Buglioni, Francesca Carocci, Menicagli Francesco, Bruno Vincenzi, Maurizio Fanciulli and Stefano Fais

    Citation: Journal of Translational Medicine 2014 12:225

    Content type: Research

    Published on:

  11. Aurora kinase A (AurkA) is over-expressed in melanoma and its inhibition has been observed to limit tumor growth, suggesting a potential role in melanoma treatment.

    Authors: Emilia Caputo, Roberta Miceli, Maria Letizia Motti, Rosarita Taté, Federica Fratangelo, Gerardo Botti, Nicola Mozzillo, Maria Vincenza Carriero, Ernesta Cavalcanti, Giuseppe Palmieri, Gennaro Ciliberto, Giuseppe Pirozzi and Paolo Antonio Ascierto

    Citation: Journal of Translational Medicine 2014 12:216

    Content type: Research

    Published on:

  12. New approaches to generate effective anticancer responses by either inducing immune responses or inhibiting immunosuppression are under development to improve efficacy in patients. On March 4-5th, 2014, a symposi...

    Authors: M Ángela Aznar, Ignacio Melero and José I Quetglas

    Citation: Journal of Translational Medicine 2014 12:202

    Content type: Meeting report

    Published on:

  13. The capacity of the recombinant Vaccinia virus GLV-1h68 as a single agent to efficiently treat different human or canine cancers has been shown in several preclinical studies. Currently, its human safety and e...

    Authors: Elisabeth Hofmann, Stephanie Weibel and Aladar A Szalay

    Citation: Journal of Translational Medicine 2014 12:197

    Content type: Research

    Published on:

  14. Our goal was to test whether short-term intermittent hypobaric hypoxia (IHH) at a level well tolerated by healthy humans could, in combination with muscle electro-stimulation (ME), mobilize circulating progeni...

    Authors: Luisa Corral, Casimiro Javierre, Juan Blasi, Ginés Viscor, Antoni Ricart and Josep Lluis Ventura

    Citation: Journal of Translational Medicine 2014 12:174

    Content type: Methodology

    Published on:

  15. The methylation inhibitor 5-Aza-2′-deoxycytidine (decitabine, DAC) has a great therapeutic value for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). But decitabine monotherapy was associated ...

    Authors: Kongfei Li, Chao Hu, Chen Mei, Zhigang Ren, Juan Carlos Vera, Zhengping Zhuang, Jie Jin and Hongyan Tong

    Citation: Journal of Translational Medicine 2014 12:167

    Content type: Research

    Published on:

  16. Alterations in key-regulator genes of disease pathogenesis (BRAF, cKIT, CyclinD1) have been evaluated in patients with multiple primary melanoma (MPM).

    Authors: Maria Colombino, MariaCristina Sini, Amelia Lissia, Vincenzo De Giorgi, Ignazio Stanganelli, Fabrizio Ayala, Daniela Massi, Corrado Rubino, Antonella Manca, Panagiotis Paliogiannis, Susanna Rossari, Serena Magi, Laura Mazzoni, Gerardo Botti, Mariaelena Capone, Marco Palla…

    Citation: Journal of Translational Medicine 2014 12:117

    Content type: Research

    Published on:

  17. Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH c...

    Authors: Pengfei Jiang, Rajesh Mukthavavam, Ying Chao, Ila Sri Bharati, Valentina Fogal, Sandra Pastorino, Xiuli Cong, Natsuko Nomura, Matt Gallagher, Taher Abbasi, Shireen Vali, Sandeep C Pingle, Milan Makale and Santosh Kesari

    Citation: Journal of Translational Medicine 2014 12:13

    Content type: Research

    Published on:

    The Erratum to this article has been published in Journal of Translational Medicine 2014 12:126

  18. This study tested the hypothesis that exendin-4 and sitagliptin can effectively protect kidney from acute ischemia-reperfusion (IR) injury.

    Authors: Yen-Ta Chen, Tzu-Hsien Tsai, Chih-Chau Yang, Cheuk-Kwan Sun, Li-Teh Chang, Hung-Hwa Chen, Chia-Lo Chang, Pei-Hsun Sung, Yen-Yi Zhen, Steve Leu, Hsueh-Wen Chang, Yung-Lung Chen and Hon-Kan Yip

    Citation: Journal of Translational Medicine 2013 11:270

    Content type: Research

    Published on:

  19. Major goals in translational oncology are to reduce systemic toxicity of current anticancer strategies and improve effectiveness. An extremely efficient cancer cell mechanism to avoid and/or reduce the effects...

    Authors: Stefano Ferrari, Francesca Perut, Franca Fagioli, Adalberto Brach Del Prever, Cristina Meazza, Antonina Parafioriti, Piero Picci, Marco Gambarotti, Sofia Avnet, Nicola Baldini and Stefano Fais

    Citation: Journal of Translational Medicine 2013 11:268

    Content type: Research

    Published on:

  20. Homoharringtonine (HHT) is a kind of cephalotaxus alkaloid used in traditional Chinese medicine. Although HHT has been successfully used as a therapeutic agent for leukemia, the drug resistance and toxicity ar...

    Authors: MinRan Zhou, JiPing Zeng, XiaoMing Wang, Qing Guo, Tao Huang, HaiYu Shen, Yue Fu, LiXiang Wang, JiHui Jia and ChunYan Chen

    Citation: Journal of Translational Medicine 2013 11:265

    Content type: Research

    Published on:

  21. 5-fluorouracil (5-FU) and cisplatin (CDDP) are used to enhance radiotherapy (RT) effect for head and neck (HN) cancers. However, the effect of local RT on systemic chemotherapeutics remains unclear. Here, we e...

    Authors: Chen-Hsi Hsieh, Mei-Ling Hou, Meng-Hsuan Chiang, Hung-Chi Tai, Hui-Ju Tien, Li-Ying Wang, Tung-Hu Tsai and Yu-Jen Chen

    Citation: Journal of Translational Medicine 2013 11:231

    Content type: Research

    Published on:

  22. This study was to investigate the effects and safety of cathepsin B-cleavable doxorubicin (DOX)-prodrug (PDOX) for targeting therapy of metastatic human hepatocellular carcinoma (HCC) using DOX as a positive c...

    Authors: Qun Wang, Yan-Jun Zhong, Jing-Ping Yuan, Li-Hua Shao, Jue Zhang, Li Tang, Shao-Ping Liu, Ya-Ping Hong, Raymond A Firestone and Yan Li

    Citation: Journal of Translational Medicine 2013 11:192

    Content type: Research

    Published on:

  23. Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors. However, a limitation to such treatment is the occurrence of resistance. Several mechanisms have been identified to be r...

    Authors: Luigi Fattore, Emanuele Marra, Maria Elena Pisanu, Alessia Noto, Claudia de Vitis, Francesca Belleudi, Luigi Aurisicchio, Rita Mancini, Maria Rosaria Torrisi, Paolo Antonio Ascierto and Gennaro Ciliberto

    Citation: Journal of Translational Medicine 2013 11:180

    Content type: Research

    Published on:

  24. Cancer vaccines are considered a promising therapeutic approach. However, their clinical results are not yet satisfactory. This may be due to the the difficulty of selection of an efficient tumor associated an...

    Authors: Francesca Kalli, Rodolfo Machiorlatti, Florinda Battaglia, Alessia Parodi, Giuseppina Conteduca, Francesca Ferrera, Michele Proietti, Samuele Tardito, Marina Sanguineti, Enrico Millo, Daniela Fenoglio, Raffaele De Palma, Giorgio Inghirami and Gilberto Filaci

    Citation: Journal of Translational Medicine 2013 11:120

    Content type: Research

    Published on:

  25. Diabetes mellitus is affecting more than 300 million people worldwide. Current treatment strategies cannot prevent secondary complications. Stem cells due to their regenerative power have long been the attract...

    Authors: Muhammad Tariq, Muhammad Sharif Masoud, Azra Mehmood, Shaheen N Khan and Sheikh Riazuddin

    Citation: Journal of Translational Medicine 2013 11:115

    Content type: Research

    Published on:

  26. DNA electroporation has been demonstrated in preclinical models to be a promising strategy to improve cancer immunity, especially when combined with other genetic vaccines in heterologous prime-boost protocols...

    Authors: Claudia Marcela Diaz, Alberto Chiappori, Luigi Aurisicchio, Ansuman Bagchi, Jason Clark, Sheri Dubey, Arthur Fridman, Jesus C Fabregas, John Marshall, Elisa Scarselli, Nicola La Monica, Gennaro Ciliberto and Alberto J Montero

    Citation: Journal of Translational Medicine 2013 11:62

    Content type: Research

    Published on:

  27. Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experie...

    Authors: Paolo Antonio Ascierto, Ester Simeone, Antonio Maria Grimaldi, Marcello Curvietto, Assunta Esposito, Giuseppe Palmieri and Nicola Mozzillo

    Citation: Journal of Translational Medicine 2013 11:61

    Content type: Commentary

    Published on:

  28. The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 facto...

    Authors: Antonio Daponte, Simona Signoriello, Luigi Maiorino, Bruno Massidda, Ester Simeone, Antonio Maria Grimaldi, Corrado Caracò, Giuseppe Palmieri, Antonio Cossu, Gerardo Botti, Antonella Petrillo, Secondo Lastoria, Ernesta Cavalcanti, Pasquale Aprea, Nicola Mozzillo, Ciro Gallo…

    Citation: Journal of Translational Medicine 2013 11:38

    Content type: Protocol

    Published on:

  29. To mimic clinical treatment situations in advanced human ovarian disease, we tested the efficacy of CpG-oligodeoxynucleotides (CpG-ODN), synthetic DNA sequences recognized by Toll-like receptor 9 and able to i...

    Authors: Michele Sommariva, Michelandrea de Cesare, Alessandra Meini, Alessandra Cataldo, Nadia Zaffaroni, Elda Tagliabue and Andrea Balsari

    Citation: Journal of Translational Medicine 2013 11:25

    Content type: Research

    Published on:

  30. Membrane-bound phospholipid scramblase 1 (PLSCR1) is involved in both lipid trafficking and cell signaling. Previously, we showed that PLSCR1 is overexpressed in many colorectal carcinomas (CRCs). In the prese...

    Authors: Chung-Wei Fan, Chun-Yu Chen, Kuei-Tien Chen, Chia-Rui Shen, Yung-Bin Kuo, Ya-Shan Chen, Yeh-Pin Chou, Wei-Shan Wei and Err-Cheng Chan

    Citation: Journal of Translational Medicine 2012 10:254

    Content type: Research

    Published on:

  31. Most DNA-damaging chemotherapeutic agents activate the transcription factor nuclear factor κB (NF-κB). However, NF-κB activation can either protect from or contribute to the growth suppressive effects of the a...

    Authors: Simona Caporali, Lauretta Levati, Grazia Graziani, Alessia Muzi, Maria Grazia Atzori, Enzo Bonmassar, Giuseppe Palmieri, Paolo A Ascierto and Stefania D’Atri

    Citation: Journal of Translational Medicine 2012 10:252

    Content type: Research

    Published on:

  32. The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our...

    Authors: Consolación Melguizo, Jose Prados, Beatriz González, Raul Ortiz, Angel Concha, Pablo Juan Alvarez, Roberto Madeddu, Gloria Perazzoli, Jaime Antonio Oliver, Rodrigo López, Fernando Rodríguez-Serrano and Antonia Aránega

    Citation: Journal of Translational Medicine 2012 10:250

    Content type: Research

    Published on:

  33. The vast majority of patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab eventually develop resistance to this agent. There is an unmet need therefore, for identifying biologica...

    Authors: George Fountzilas, Christos Christodoulou, Mattheos Bobos, Vassiliki Kotoula, Anastasia G Eleftheraki, Ioannis Xanthakis, Anna Batistatou, George Pentheroudakis, Nikolaos Xiros, Irene Papaspirou, Anna Koumarianou, Pavlos Papakostas, Dimitrios Bafaloukos, Dimosthenis V Skarlos and Konstantine T Kalogeras

    Citation: Journal of Translational Medicine 2012 10:212

    Content type: Research

    Published on:

  34. The concept of tissue banking as a “bio-repository” aimed to collection, storing and distribution of human biological material and clinical information, is emerging as a successful strategy to support clinical...

    Authors: Gerardo Botti, Renato Franco, Monica Cantile, Gennaro Ciliberto and Paolo Antonio Ascierto

    Citation: Journal of Translational Medicine 2012 10:204

    Content type: Editorial

    Published on:

  35. Role of KRAS, BRAF and PIK3CA mutations in pathogenesis of colorectal cancer (CRC) has been recently investigated worldwide. In this population-based study, we evaluated the incidence rates and distribution of su...

    Authors: Grazia Palomba, Maria Colombino, Antonio Contu, Bruno Massidda, Giovanni Baldino, Antonio Pazzola, MariaTeresa Ionta, Francesca Capelli, Vittorio Trova, Tito Sedda, Giovanni Sanna, Francesco Tanda, Mario Budroni, Giuseppe Palmieri and Antonio Cossu

    Citation: Journal of Translational Medicine 2012 10:178

    Content type: Research

    Published on:

  36. Sunitinib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and stem cell factor receptor (KIT). The ability of soluble (s)KIT, VEGF-A, sVEGFR-2, and sVE...

    Authors: Kiana Keyvanjah, Samuel E DePrimo, Charles S Harmon, Xin Huang, Kenneth A Kern and William Carley

    Citation: Journal of Translational Medicine 2012 10:165

    Content type: Research

    Published on:

  37. Procedural failure and untoward clinical outcomes after surgery remain problematic in critical limb ischemia (CLI) patients. This study tested a clopidogrel-cilostazol combination treatment compared with eithe...

    Authors: Jiunn-Jye Sheu, Kun-Chen Lin, Ching-Yen Tsai, Tzu-Hsien Tsai, Steve Leu, Chia-Hung Yen, Yung-Lung Chen, Hsueh-Wen Chang, Cheuk-Kwan Sun, Sarah Chua, Jenq-Lin Yang and Hon-Kan Yip

    Citation: Journal of Translational Medicine 2012 10:164

    Content type: Research

    Published on:

  38. Out of hospital cardiac arrest (OHCA) has a poor outcome. Recent non-randomized studies of ECLS (extracorporeal life support) in OHCA suggested further prospective multicenter studies to define population that...

    Authors: Jan Belohlavek, Karel Kucera, Jiri Jarkovsky, Ondrej Franek, Milana Pokorna, Jiri Danda, Roman Skripsky, Vit Kandrnal, Martin Balik, Jan Kunstyr, Jan Horak, Ondrej Smid, Jaroslav Valasek, Vratislav Mrazek, Zdenek Schwarz and Ales Linhart

    Citation: Journal of Translational Medicine 2012 10:163

    Content type: Protocol

    Published on:

  39. P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clinical trials. Gemcitabine is a standard of care for the treatment of pancreatic cancer. The present study investigated the effect o...

    Authors: Maggie J Rathos, Kavita Joshi, Harshal Khanwalkar, Sonal M Manohar and Kalpana S Joshi

    Citation: Journal of Translational Medicine 2012 10:161

    Content type: Research

    Published on:

  40. Previous studies have shown that long-term oral daily PDE 5 inhibitors (PDE5i) counteract fibrosis, cell loss, and the resulting dysfunction in tissues of various rat organs and that implantation of skeletal m...

    Authors: Judy SC Wang, Istvan Kovanecz, Dolores Vernet, Gaby Nolazco, George E Kopchok, Sheryl L Chow, Rodney A White and Nestor F Gonzalez-Cadavid

    Citation: Journal of Translational Medicine 2012 10:159

    Content type: Research

    Published on:

  41. Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clini...

    Authors: Wenshi Wang, Daohai Yu, Amod A Sarnaik, Bin Yu, Maclean Hall, Dawn Morelli, Yonghong Zhang, Xiuhua Zhao and Jeffrey S Weber

    Citation: Journal of Translational Medicine 2012 10:146

    Content type: Research

    Published on:

  42. After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunizat...

    Authors: Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, Mark B Faries, Soldano Ferrone, Keith Flaherty, Bernard A Fox, Thomas F Gajewski, Jeffrey E Gershenwald, Helen Gogas, Kenneth Grossmann, Axel Hauschild, F Stephen Hodi, Richard Kefford, John M Kirkwood, Sancy Leachmann…

    Citation: Journal of Translational Medicine 2012 10:83

    Content type: Meeting report

    Published on:

  43. Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth, immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30–100 nm membra...

    Authors: Annette M Marleau, Chien-Shing Chen, James A Joyce and Richard H Tullis

    Citation: Journal of Translational Medicine 2012 10:134

    Content type: Review

    Published on:

  44. Adeno-associated vectors (rAAV) have been used to attain long-term liver gene expression. In humans, the cellular immune response poses a serious obstacle for transgene persistence while neutralizing humoral i...

    Authors: Carmen Unzu, Sandra Hervás-Stubbs, Ana Sampedro, Itsaso Mauleón, Uxua Mancheño, Carlos Alfaro, Rafael Enríquez de Salamanca, Alberto Benito, Stuart G Beattie, Harald Petry, Jesús Prieto, Ignacio Melero and Antonio Fontanellas

    Citation: Journal of Translational Medicine 2012 10:122

    Content type: Research

    Published on:

  45. At recurrence the use of nitrosoureas is widely-used as a therapeutic option for glioblastoma (GBM) patients. The efficacy of fotemustine (FTM) has been demonstrated in phase II clinical trials; however, these...

    Authors: Alessandro Paccapelo, Ivan Lolli, Maria Grazia Fabrini, Giovanni Silvano, Beatrice Detti, Franco Perrone, Giuseppina Savio, Matteo Santoni, Erminio Bonizzoni, Tania Perrone and Silvia Scoccianti

    Citation: Journal of Translational Medicine 2012 10:90

    Content type: Research

    Published on:

  46. Clinical observations suggested that a non negligible proportion of patients, ranging from 40% to 70%, does not seem to benefit from the use of anti-EGFR targeted antibodies even in the absence of a mutation o...

    Authors: Mario Scartozzi, Riccardo Giampieri, Elena Maccaroni, Alessandra Mandolesi, Simona Biagetti, Simona Alfonsi, Lucio Giustini, Cristian Loretelli, Luca Faloppi, Alessandro Bittoni, Maristella Bianconi, Michela Del Prete, Italo Bearzi and Stefano Cascinu

    Citation: Journal of Translational Medicine 2012 10:71

    Content type: Research

    Published on:

  47. The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors h...

    Authors: Gabriele Madonna, Claudio Dansky Ullman, Giusy Gentilcore, Giuseppe Palmieri and Paolo Antonio Ascierto

    Citation: Journal of Translational Medicine 2012 10:53

    Content type: Review

    Published on:

  48. The aim of the present study was to analyse the expression of Secreted protein acidic and rich in cysteine (SPARC) in nasopharyngeal carcinoma (NPC) specimens, and to evaluate its correlation with clinicopatho...

    Authors: Hai-Yun Wang, Yang-Yang Li, Qiong Shao, Jing-Hui Hou, Fang Wang, Man-Bo Cai, Yi-Xin Zeng and Jian-Yong Shao

    Citation: Journal of Translational Medicine 2012 10:27

    Content type: Research

    Published on:

  49. Shuanglong formula (SLF), a Chinese medicine composed of panax ginseng and salvia miltiorrhiza exhibited significant effect in the treatment of myocardial infarction (MI) in clinical. Because of the complex natur...

    Authors: Qiong-Lin Liang, Xiao-Ping Liang, Yi-Ming Wang, Yuan-Yuan Xie, Rong-Li Zhang, Xi Chen, Rong Gao, Yi-Jun Cheng, Jun Wu, Qing-Bo Xu, Qing-Zhong Xiao, Xue Li, Shu-Feng Lv, Xue-Mei Fan, Hong-Yang Zhang, Qing-Li Zhang…

    Citation: Journal of Translational Medicine 2012 10:26

    Content type: Research

    Published on:

Annual Journal Metrics

Advertisement